The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, " Actionable structural variant ...

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...

Qiagen (QGEN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel Brennan from ...

Randomized controlled trials evaluating different sequencing strategies for initiating and titrating these medications are lacking. We sought to compare costs for various HFrEF quadruple therapy ...

QuantumScape released its Q3 2024 business report this afternoon, and the biggest news is an update regarding the progress of its solid-state battery development and production. According to the ...

These next-generation sequencing (NGS) tests deliver better diagnostic value and cost-effectiveness than single gene testing and direct the first-line treatment of diverse solid tumors ...

Today’s LoLdle was another easy one after yesterday’s walk in the park. I got it on my first try, but if you didn’t, read on for the answer to the Oct. 18 quote. Only two champions are ...